Published Data in Metastatic Ocular Melanoma
SIR-Spheres® Y-90 resin microspheres have shown benefits in the first-line treatment of treatment-refractory liver metastases from melanoma (predominantly from ocular or uveal primary tumours).
In a mixed population of patients with unresectable cutaneous or ocular metastatic melanoma that was refractory to systemic therapy, SIR-Spheres Y-90 resin microspheres were associated with longer survival from diagnosis of the metastatic melanoma than best supportive care (19.9 months vs. 4.8 months).1 Other non-comparative studies of SIRT with SIR-Spheres Y-90 resin microspheres for metastatic melanoma have demonstrated similar or longer survival from diagnosis (19.0–23.9 months).2,3
SIR-Spheres Y-90 resin microspheres are generally well tolerated in this clinical setting.
1 Xing M. et al. Am J Clin Oncol 2014 Aug 1; ePub doi: 10.1097/COC.0000000000000109.
2 Klingenstein A. et al. Cardiovasc Intervent Radiol 2013; 36: 158-165.
3 Eldredge-Hindy H. et al. Am J Clin Oncol 2016; 39: 189-195.
Ongoing mOM Studies
Ongoing studies of SIR-Spheres® Y-90 resin microspheres in the treatment of mOM:
|Title||Setting||Sponsor||Study ID||Treatment Arm(s)||N||Location|
SIR-Spheres microspheres treatment of uveal melanoma metastasised to liver
|Uveal melanoma||Investigator-Initiated Research Study||NCT01473004||SIR-Spheres Y-90 resin microspheres||48||USA|
SIR-Spheres microspheres vs. TACE treatment of uveal melanoma metastasised to liver
|Uveal melanoma||Investigator-Initiated Research Study||NCT02936388||SIR-Spheres Y-90 resin microspheres vs. TACE (cisplatin+embocept)||108||Germany|
Sorafenib and radioembolisation with SIR Spheres for the treatment of metastatic ocular melanoma
|Uveal melanoma||Investigator-Initiated Research Study||NCT01893099||SIR Spheres Y-90 resin microspheres > sorafenib or sorafenib > SIR Spheres Y-90 resin microspheres||24||Switzerland|